Eli Lilly has put serious money behind its AI drug development push, striking a deal worth up to $2.75 billion with Hong Kong-based Insilico Medicine.
Eli Lilly $LLY has signed an AI-powered drug development deal with Insilico Medicine that could be worth up to $2.75 billion
Under the deal:
– Insilico is eligible for $115M in upfront payments; other milestones could bring the value to $2.75B, plus tiered royalties on future… pic.twitter.com/VrCwqqkysG
— Evan (@StockMKTNewz) March 29, 2026
The agreement, announced Sunday, hands Insilico $115 million upfront. The rest depends on regulatory and commercial milestones, plus royalties on future sales.
Lilly gets exclusive global rights to develop and sell any treatments that come out of the partnership. That’s a wide runway for a company already flush with cash from its obesity drug success.
Insilico has built its reputation on running AI across the entire drug discovery process — from identifying biological targets to designing the actual compounds. The company says it has developed more than 28 drugs using generative AI, with nearly half already in clinical-stage trials.
Insilico went public in Hong Kong in December and its stock is up more than 50% year-to-date.
The two companies aren’t starting from scratch. They first worked together in 2023 under an AI-based software licensing agreement. Sunday’s deal is a major step up from that.
Andrew Adams, group vice president of Molecule Discovery at Lilly, said Insilico’s AI platform is “a powerful complement” to Lilly’s own clinical development work. He said the collaboration would help explore new mechanisms and speed up the identification of drug candidates across multiple disease areas.
Insilico CEO Alex Zhavoronkov was candid about what makes Lilly an attractive partner. “In many ways, Lilly is better than us in some areas of AI,” he said, pointing to the pharma giant’s ability to bring biology, chemistry, and automation together.
Insilico develops its AI technology outside China — primarily in Canada and the Middle East — but runs early preclinical work in China. Zhavoronkov says AI can synthesize molecules faster than traditional methods, cutting down research timelines considerably.
As part of the deal, Insilico will join Lilly’s Gateway Labs community, a biotech development network. No specific disease areas have been disclosed yet.
Lilly has been on an infrastructure spending spree. The company is building a research hub in San Francisco and investing in advanced computing systems. It also announced plans to invest $3 billion in China over the next decade, a market that currently makes up just under 3% of its revenue.
CEO David Ricks attended a high-level forum in Beijing earlier this month, underlining the company’s growing focus on China-linked opportunities even as it expands globally.
Lilly’s executives have made clear the goal is to use AI to find new biological targets faster and build a pipeline that extends beyond its current blockbuster weight-loss treatments.
The Insilico deal gives Lilly a direct line to one of the more advanced AI drug discovery platforms currently operating, with a portfolio already deep into clinical testing.
The post Eli Lilly (LLY) Signs $2.75B Deal for AI-Developed Drugs From Insilico appeared first on CoinCentral.
